INS and type 1 diabetes mellitus: Although these technologies have been shown to reduce the incidence of severe hypoglycaemic events, including those leading to hypoglycaemic seizure or coma,10 they do not address the issue of variability in insulin requirements,11 which remains an unmet need in patients with type 1 diabetes.